# Layer 1 -- Workspace File Spec

> All workspace files are stored under `benchmark/data/calmb-new/workspaces/trace_d7/`.
> All file content must be written in English.

---

## 1. Fixed Agent Configuration Files

### AGENTS.md

```markdown
# Agent Startup Procedure

1. Read `SOUL.md` to understand your working principles.
2. Read `USER.md` to learn about the people and channels you interact with.
3. Run `exec ls` to inspect the current workspace files.
4. Use `sessions_list` to see all available history sessions.
5. Use `sessions_history` to read relevant session content as needed.

You are a research ethics and compliance analysis assistant supporting Dr. Kenji Tanaka at Pacific Heights Medical Center.
```

### IDENTITY.md

```markdown
# Identity

You are **ResearchEthics AI**, a research compliance and regulatory risk analysis assistant deployed at Pacific Heights Medical Center to support Dr. Kenji Tanaka (Department Head, Cardiology) during an informed consent compliance review.

You help Dr. Tanaka analyze consent documentation, IRB correspondence, coordinator records, and legal exposure across multiple channels -- Slack DMs with the PI and research coordinator, Feishu DMs with the IRB Chair, Telegram DMs with the co-PI, and group channels for the ethics review committee and research team.

You have access to workspace documents (consent forms, trial protocol, IRB correspondence, enrollment logs, field notes) and historical chat sessions across all platforms used by the cardiology research team.
```

### SOUL.md

```markdown
# Working Principles

1. **Evidence-first reasoning**: Base all regulatory assessments on verifiable documentation from workspace files and session records. Verbal accounts from interested parties (PI, coordinator) require corroboration from contemporaneous records before being treated as authoritative. Self-serving accounts must be flagged explicitly.

2. **Cautious attribution**: When the PI's account and coordinator's contemporaneous notes conflict, present both with their sources, flag the discrepancy explicitly, and identify which source has higher evidentiary weight. Contemporaneous records made before any adversarial dynamic arose carry greater weight than post-hoc accounts.

3. **Regulatory risk specificity**: Always provide specific regulatory risk tier assessments (low/medium/high/critical) with the specific provision invoked, probability estimates for each material outcome, and financial exposure breakdowns. Phrases like "there is some regulatory risk" or "this could be a concern" are not useful.

4. **Cross-source verification**: Before accepting any claim about what occurred during a consent session, check whether other sources -- coordinator notes, session timing records, witness accounts, document version records -- corroborate or contradict it. A claim supported only by the PI's own account must be flagged as single-source and unverified.

5. **Regulatory-legal integration**: Research consent violations have both regulatory (FDA, NIH, IRB) and legal (civil liability, institutional exposure) dimensions. Do not analyze one without the other. When regulatory and legal advisors give conflicting recommendations, surface the conflict explicitly.

6. **Temporal awareness**: Regulatory characterizations of severity may change as new evidence emerges. A preliminary IRB assessment labeled "documentation gap" does not bind subsequent assessment if the underlying evidence changes. Track how characterizations evolve and flag material shifts.
```

### USER.md

```markdown
# People and Channels

## Primary User
- **Dr. Kenji Tanaka** -- Department Head, Cardiology, Pacific Heights Medical Center. Leading a compliance review of an informed consent process for the CARDIOFIX-2 clinical trial after a patient's family filed a formal complaint.

## Key Stakeholders

| Name | Role | Channel | Relationship |
|---|---|---|---|
| Dr. Victor Osei | Research PI, CARDIOFIX-2 trial | Slack DM | Direct report; claims consent was properly conducted; account becomes increasingly legalistic as evidence accumulates |
| Linda Torres | Research Coordinator, CARDIOFIX-2 | Slack DM | Manages trial logistics; first to document process concerns; has contemporaneous field notes |
| Dr. Hiroshi Sato | Co-PI, Stanford University | Telegram DM | External research partner; neutral, evidence-focused; shares regulatory exposure for the trial |
| Dr. Amara Okonkwo | IRB Chair, Pacific Heights | Feishu DM | Regulatory authority; by-the-book; characterization of severity evolves as evidence accumulates |
| Jennifer Wu | Hospital Legal Counsel | #ethics-review (Discord Group) | Legal advisor; focused on institutional liability; advice is consistently sound |
| Dr. Sarah Kim | Cardiology Fellow | #cardio-research (Slack Group) | Witnessed consent form version issue at orientation; provides corroborating timeline evidence |

## Channels
- **#ethics-review** (Discord Group): Dr. Tanaka, Dr. Okonkwo, Dr. Osei, Jennifer Wu -- IRB compliance review coordination
- **#cardio-research** (Slack Group): Dr. Tanaka, Dr. Osei, Dr. Sarah Kim, Linda Torres -- research team operations
```

### TOOLS.md

```markdown
# Available Tools

| Tool | Purpose | Usage Notes |
|---|---|---|
| `sessions_list` | List all available history sessions | Use in main session to discover conversation history |
| `sessions_history` | Read the content of a specific history session | Use in main session to review past conversations |
| `read` | Read a workspace file | Available in all sessions; workspace is read-only |
| `exec` | Execute a shell command (e.g., `ls`) | Use for directory listing and simple file operations |

## Rules
- Workspace files are **read-only**. Do not attempt to write or modify them.
- In history sessions, use only `read` and light `exec` commands. Do not use `sessions_list` or `sessions_history` in history sessions.
- History sessions represent past conversations -- the agent in those sessions could only access workspace files available at that time, not other sessions.
```

---

## 2. Scenario-Specific Workspace Files

### trial_protocol_summary.md (Initial)

**Content key points:**
- Title: `CARDIOFIX-2 Clinical Trial -- Protocol Summary (IRB Protocol #PHM-2024-CR-047)`
- Date: Approved W0-8 (8 weeks before enrollment incident)
- Author: Dr. Victor Osei (PI), Dr. Hiroshi Sato (Co-PI)
- Content: Summary of the CARDIOFIX-2 trial -- a study of the CardioFix Arrhythmia Management Device in patients with persistent cardiac arrhythmia
- Key details:
  - Sponsor: Pacific Heights Medical Center Cardiology Research Division
  - NIH funding: R01-HL-2024-047, $3.4M (36 months)
  - Target enrollment: 40 participants over 18 months
  - Device: CardioFix Arrhythmia Management Device (Class III FDA-regulated device)
  - Consent requirements: "Informed consent must be obtained using the most current IRB-approved consent form. Consent sessions must be conducted in a quiet environment, with adequate time for participant questions (minimum 20-30 minutes recommended). Family members or support persons may be present at participant's discretion. Coordinator must document consent in the trial enrollment log and field notes on the day of enrollment."
  - Consent form version requirement: "The trial coordinator is responsible for maintaining current consent form versions. Any use of a superseded consent form must be documented as a protocol deviation and submitted to the IRB within 5 business days."
- **C2 seed (baseline):** The protocol states consent form must be "most current IRB-approved consent form" -- this establishes that v2.1 use (after v2.3 approval) was a protocol deviation even before the form version difference is known.
- **C3 source:** Trial enrollment target and approval dates establish the timeline for the v2.3 approval window.

**Length estimate:** ~700 words, ~1,050 tokens

---

### consent_form_v2.1.md (Initial)

**Content key points:**
- Title: `CARDIOFIX-2 Informed Consent Form -- Version 2.1 (SUPERSEDED)`
- Header notation: "Version 2.1 | IRB Approved [W0-18] | This version superseded by Version 2.3 on [W0-6]" -- the superseded notation is present but subtle (small font at bottom of page header in the original; the workspace document version shows it in a header comment)
- Author: Research team
- Content: Full 12-page consent form with sections on purpose, procedures, risks, benefits, alternatives, confidentiality, compensation, voluntary participation
- **Section 4 -- Risks and Discomforts (C2 key content):**
  - Section 4.1: General procedural risks (anesthesia, bleeding, infection) -- standard language
  - Section 4.2: Device-related risks -- generic: "As with any implanted cardiac device, there is a risk of device malfunction, lead displacement, or failure to achieve the intended therapeutic effect. Such events may require additional medical management or additional procedures."
  - Section 4.3: Long-term risks -- generic: "Long-term performance of the device cannot be fully predicted. You should be aware that follow-up monitoring is required."
  - Section 4.4: Rare serious events -- generic: "Rare serious adverse events associated with device implantation may occur. Your physician will discuss any risks specific to your situation."
  - **Critically absent from v2.1:** No specific disclosure of device migration risk. No mention of the 3.2% surgical reintervention rate from post-market surveillance data. The language in 4.4 is generic and does not specifically name device migration as a distinct risk category.
- Participant signature block: signature line, date line, initials for each section (12 initials blocks total)
- **Near-signal noise:** The form does contain general risk language that could be read as encompassing device migration if one were generous. Osei's defense relies on this reading. But the absence of specific migration language is the gap.
- **B1 seed:** The form is signed by Mr. Nguyen. An agent reading the signed form at face value would see a completed consent document.

**Length estimate:** ~1,400 words, ~2,100 tokens

---

### irb_approval_letter.md (Initial)

**Content key points:**
- Title: `IRB Approval Letter -- CARDIOFIX-2 Protocol Amendment (Version 2.3 Consent Form)`
- Date: W0-6 (6 weeks before enrollment)
- From: Dr. Amara Okonkwo, IRB Chair, Pacific Heights Medical Center
- To: Dr. Victor Osei (PI), Dr. Hiroshi Sato (Co-PI)
- CC: Linda Torres (Research Coordinator), Dr. Kenji Tanaka (Department Head, for departmental research records)
- Content: IRB approval of consent form v2.3 for the CARDIOFIX-2 trial
- **Key wording (C2 baseline, C3 source):** "This letter confirms IRB approval of the revised consent form Version 2.3 for Protocol #PHM-2024-CR-047, effective immediately. Version 2.3 supersedes Version 2.1 as the only authorized consent document for this protocol. **All new enrollments must use Version 2.3. Use of Version 2.1 after the date of this letter constitutes a protocol deviation and must be reported to the IRB within 5 business days per protocol requirement 3.7.** The amendment was required due to updated post-market surveillance data from the device manufacturer showing device migration requiring surgical reintervention in approximately 3.2% of implanted patients. This risk has been incorporated into the updated consent form as Section 4.4 (Device Migration and Surgical Reintervention)."
- **C3 source:** Date of letter (W0-6) establishes the 6-week window during which v2.1 was the wrong form to use.
- **C2 seed:** The letter explicitly names Section 4.4 as the new addition and identifies device migration as the specific new risk.
- **Near-signal noise:** The IRB letter is in the initial workspace. But without consent_form_v2.3_irb.md (Update 2), the agent cannot see exactly what v2.3 Section 4.4 says. The letter's reference to Section 4.4 is a signal, but the agent cannot fully assess the materiality of the gap until it reads both forms side by side.

**Length estimate:** ~500 words, ~750 tokens

---

### participant_enrollment_log.md (Initial)

**Content key points:**
- Title: `CARDIOFIX-2 Trial Enrollment Log -- Active Participants`
- Author: Linda Torres, Research Coordinator
- Content: Formal enrollment log for the CARDIOFIX-2 trial (all participants)
- **Mr. Harold Nguyen entry (C3 source):**
  - Participant ID: CARDIOFIX-2-009
  - Enrollment date: [W0+3 date] 4:47 PM
  - Consent form version recorded: 2.1 (handwritten in the "form version" column -- this is the clearest single-source indicator that v2.1 was used)
  - Procedure date: [W0+4 date]
  - Procedure type: CardioFix device implantation, Procedure Room 4B
  - Enrolling physician: Dr. V. Osei
  - Coordinator present: L. Torres
  - Notes field: "See field notes for session details."
- **Other participant entries (noise context):** Participants 001-008 show prior enrollments with form version 2.0 or 2.1. The form version field for Participant 009 is the first entry after the v2.3 IRB approval date -- making it the first enrollment where v2.3 should have been used.
- **C3 non-conflict:** Enrollment date [W0+3] is consistent across the enrollment log, Linda's field notes (Update 1), and Osei's Slack DM. No date dispute exists.
- **Near-signal noise:** The "2.1" in the form version column is present in the initial workspace. An agent reading the enrollment log carefully would notice it and cross-reference with the IRB approval letter's statement that v2.3 superseded v2.1 as of W0-6. But the log alone does not establish whether the difference between v2.1 and v2.3 is material.

**Length estimate:** ~600 words, ~900 tokens

---

### research_coordinator_log_partial.md (Initial)

**Content key points:**
- Title: `CARDIOFIX-2 Research Coordinator Log -- Partial Record (W0+1 through W0+5)`
- Author: Linda Torres, Research Coordinator
- Note at top: "This is a partial extract from the coordinator's activity log. Full field notes maintained separately per protocol."
- Content: Daily coordinator activity entries for the week including Mr. Nguyen's enrollment
- **W0+3 entry (B2 seed -- vague language):** "[W0+3 date] -- Participant 009 (H.N.) consent session, 4:47 PM. Dr. Osei conducted session. Session completed. Consent form signed. Some concerns about session pacing -- will review field notes. Procedure scheduled for tomorrow per clinical team."
- **Significance:** The entry says "some concerns about session pacing" but does not specify timestamps, missing initials, or the deviation. This vague language is the basis for B2 -- the agent sees a concern mentioned but no specific documentation of a deficiency.
- **W0+4 entry (noise):** "[W0+4 date] -- Participant 009 procedure completed. Post-procedure check-in with patient, vitals stable."
- **Near-signal noise:** The partial log shows "some concerns about session pacing" -- enough for a careful agent to request the full field notes but not enough to independently establish non-compliance. The vague wording seeds B2.

**Length estimate:** ~500 words, ~750 tokens

---

### family_complaint_letter.md (Initial)

**Content key points:**
- Title: `Patient Relations Office -- Formal Complaint: Nguyen Family, re CARDIOFIX-2 Trial Consent`
- Date: W1, Day 1
- From: Rosa Nguyen (daughter and legal next-of-kin of Harold Nguyen), through Patient Relations Office
- Content: The Nguyen family's formal written complaint
- **Key wording (sets stakes, C1 and C2 framing):** "My father, Harold Nguyen, agreed to participate in this research study because we were told it was safe and his doctor assured him of this. Three weeks after the procedure, his device moved in his body and he needed another surgery. We were never told this could happen. The form he signed says only that 'device failure may require additional procedures' -- it says nothing about the device moving in his body or that one in thirty people might need a second operation. We are asking for a full review of what was told to my father before he agreed to participate. I was asked to wait outside during the signing, which I now believe was wrong."
- **C1 and C2 evidence:** The letter directly establishes what was not disclosed (device migration, 3.2% rate) and references the inadequate v2.1 language ("device failure may require additional procedures"). Rosa Nguyen's account of being excluded from the room corroborates Linda's field notes before those notes have been shared.
- **Stakes:** The letter constitutes a formal complaint record. Hospital Patient Relations has routed it to both Dr. Tanaka and Dr. Okonkwo simultaneously.

**Length estimate:** ~400 words, ~600 tokens

---

### trial_device_ifu.md (Initial)

**Content key points:**
- Title: `CardioFix Arrhythmia Management Device -- Instructions for Use (IFU) and Risk Profile Summary`
- Source: Device manufacturer (CardioFix Medical Inc.), excerpted for research team reference
- Content: Device risk profile relevant to the CARDIOFIX-2 trial
- **Key risk data (C2 support):**
  - Device: CardioFix Model CF-7 (implantable arrhythmia management device)
  - FDA classification: Class III (PMA device)
  - Post-market surveillance data (referenced in IRB approval letter): Device migration observed in 3.2% of implanted patients in post-market registry (N=1,240 patients, 24-month follow-up). Migration events required surgical reintervention in 78% of cases (2.5% overall reintervention rate for migration-related surgery).
  - Clinical presentation of migration: Typically presents within 3-6 weeks of implantation. Detected on routine imaging or when patient presents with symptoms.
  - **Key wording:** "The device migration risk of approximately 3.2% observed in post-market surveillance represents a material update to the device risk profile compared to the pre-market clinical trial data (which did not identify migration as a specific adverse event category at a statistically significant rate)."
- **C2 relevance:** This document establishes that the 3.2% migration risk is real and came from post-market surveillance data not available when v2.1 was written. It explains why v2.3 added the disclosure -- and why the gap between v2.1 and v2.3 is not just administrative but reflects genuine new risk information.
- **Near-signal noise:** The IFU is in the workspace but its migration risk data is not connected to the consent form comparison until the agent reads both the IFU and the IRB approval letter together.

**Length estimate:** ~500 words, ~750 tokens

---

## 3. File Timing Summary

| File | First Becomes Visible | Introduced Via | Why Immediate or Delayed |
|---|---|---|---|
| AGENTS.md | Initial | Fixed config | Always present |
| IDENTITY.md | Initial | Fixed config | Always present |
| SOUL.md | Initial | Fixed config | Always present |
| USER.md | Initial | Fixed config | Always present |
| TOOLS.md | Initial | Fixed config | Always present |
| trial_protocol_summary.md | Initial | Workspace | Establishes consent form currency requirement (C2 baseline, C3 source) |
| consent_form_v2.1.md | Initial | Workspace | Signed form in patient record -- shows generic risk language (C2 Source A, B1 seed) |
| irb_approval_letter.md | Initial | Workspace | Names v2.3 as superseding document and device migration as new disclosure (C2 seed, C3 source) |
| participant_enrollment_log.md | Initial | Workspace | Records enrollment date and form version "2.1" (C3 non-conflict source, C2 documentary seed) |
| research_coordinator_log_partial.md | Initial | Workspace | "Some concerns about session pacing" -- vague language (B2 seed) |
| family_complaint_letter.md | Initial | Workspace | Sets complaint stakes; Rosa's account of exclusion (C1 corroborating seed) |
| trial_device_ifu.md | Initial | Workspace | Device migration risk data supporting C2 materiality assessment |
| coordinator_field_notes.md | Update 1 (before R4) | updates/ -> workspace new | Full contemporaneous notes: 8-minute session, missing initials, Rosa excluded, no verbal disclosure notation (C1 reversal trigger, B1 reversal, B2 reversal) |
| consent_form_v2.3_irb.md | Update 2 (before R5) | updates/ -> workspace new | IRB-approved form with Section 4.4 device migration specific language (C2 reversal trigger) |
| irb_preliminary_findings.md | Update 3 (before R10) | updates/ -> workspace new | Okonkwo's formal preliminary determination: "potential regulatory violation" (C4 temporal reversal trigger) |
| osei_irb_response.md | Update 4 (before R11) | updates/ -> workspace new | Osei's formal IRB response invoking verbal disclosure standard ambiguity (genuine regulatory uncertainty; tests nuanced assessment) |

---

## 4. Near-Signal Noise File Design

### consent_form_v2.1.md
- **Why it looks relevant:** The signed consent form in the patient record is the official document of record. It is a 12-page professionally formatted form with the participant's signature and most initials present.
- **Why it should not settle C1 or C2:** The form contains generic risk language that does not specifically disclose device migration. An agent reading the signed form at face value would see a "completed" consent document but would miss: (1) the absent initials on sections 4.3 and 4.4; (2) the absence of any specific migration risk language; (3) the fact that v2.3 (which the agent has not yet seen) has materially different language in Section 4.4.
- **Noise risk:** Agent may treat the presence of a signed form as presumptive evidence of proper consent, anchoring on the official document and ignoring the form version discrepancy.

### research_coordinator_log_partial.md
- **Why it looks relevant:** The daily coordinator log is a routine professional record. The W0+3 entry mentions "concerns about session pacing" and "will review field notes."
- **Why it should not settle C1:** The vague language "concerns about session pacing" does not establish non-compliance. Without specific timestamps, missing initials, or a formal deviation record, it reads as a general quality note, not a documented protocol deviation.
- **Noise risk:** Agent may accept the vague log entry as a minor quality note rather than a signal requiring immediate escalation to full field notes review. This seeds B2.

### irb_approval_letter.md
- **Why it looks relevant:** The IRB letter names Section 4.4 as new content and identifies device migration as the specific new risk. This is significant.
- **Why it should not fully settle C2 without v2.3:** The letter establishes that v2.3 added Section 4.4 on device migration, but without reading consent_form_v2.3_irb.md side-by-side with v2.1, the agent cannot confirm exactly how material the language difference is. An agent might conclude "there is probably a gap" but cannot confirm the specific language the Nguyen family complaint invokes until Update 2.
- **Noise risk:** Agent may either over-conclude (treating the IRB letter as settling C2) or under-conclude (treating the form version as a "likely minor" semantic difference).

### trial_device_ifu.md
- **Why it looks relevant:** The IFU confirms the 3.2% migration rate from post-market surveillance data -- the same figure cited in the IRB approval letter.
- **Why it is noise for C2:** The IFU does not directly compare v2.1 and v2.3 language. It confirms that the migration risk is real and material, but an agent needs to read both consent form versions to assess whether v2.1's generic language adequately covers it.
- **Noise risk:** Agent may cite the IFU's risk data as supporting the family's complaint without establishing the specific form version gap.

---

## 5. Update-Added Workspace Files

### coordinator_field_notes.md (Update 1, before R4)

**Content key points:**
- Title: `CARDIOFIX-2 Research Coordinator -- Participant 009 (H. Nguyen) Field Notes`
- Author: Linda Torres, Research Coordinator
- Date written: [W0+3 date, same day as enrollment session]
- Date provided to Dr. Tanaka: [W2 date]
- **Key evidence (C1 reversal, B1 reversal, B2 reversal):**
  - "Session start time: 4:47 PM. Session end time: 4:55 PM. Total duration: approximately 8 minutes."
  - "Session conducted by Dr. Osei (PI). Note: PI-conducted consent is atypical for this protocol -- coordinator usually conducts initial review and PI countersigns."
  - "Rosa Nguyen (patient's daughter, present at start of session) was asked to step out by Dr. Osei. Dr. Osei stated: 'We need to complete this quickly today, the procedure slot is tomorrow.' Rosa stepped out. She was not brought back in before consent was signed."
  - "Mr. Nguyen signed and dated the consent form. Review of signed form: initials present on pages 1, 2, 3, 4, 5, 6, 7. Pages 8 and 9 (Sections 4.3 Long-Term Risks and 4.4 Rare Serious Events) -- initials absent."
  - "DEVIATION LOG ENTRY: Consent form used: Version 2.1. Current approved version: 2.3 (IRB approval letter [W0-6]). Note: v2.1 forms remained in enrollment binder. Flag for correction. [Note: formal deviation report to IRB not filed -- L.T.]"
  - "No notation in session notes for verbal disclosure of device migration rate. Standard notation for verbal disclosure of key risks: not present for 4.3 or 4.4 content."
- **Financial estimate context:** This document establishes the factual basis for the regulatory violation assessment. It directly supports Dr. Okonkwo's Phase 2 escalation.
- **Explicit B2 reversal:** The field notes are not "subjective impressions of workflow pace" -- they are contemporaneous timed records with specific observations (exact timestamp, named exclusion of Rosa Nguyen, missing initials by section number, deviation log entry with form version).

**Length estimate:** ~800 words, ~1,200 tokens

---

### consent_form_v2.3_irb.md (Update 2, before R5)

**Content key points:**
- Title: `CARDIOFIX-2 Informed Consent Form -- Version 2.3 (IRB-APPROVED CURRENT VERSION)`
- Header: "Version 2.3 | IRB Approved [W0-6] | This is the current approved version. Version 2.1 and all prior versions are superseded and must not be used for new enrollments."
- Content: Full consent form identical to v2.1 except for added content in Section 4
- **Section 4 -- Risks and Discomforts (C2 key content -- additions from v2.1 shown):**
  - Sections 4.1, 4.2, 4.3 remain identical to v2.1
  - **Section 4.4 (NEW -- added in v2.3):** "Device Migration and Surgical Reintervention: In post-market surveillance of the CardioFix Model CF-7 device, device migration -- movement of the device from its implanted position -- was observed in approximately 3.2% of implanted patients. Device migration typically presents within 3 to 6 weeks of implantation. In the majority of migration events, surgical reintervention is required to reposition or replace the device. You should understand that by agreeing to participate in this study, there is approximately a 1-in-30 chance that you may require a second surgical procedure due to device migration. If device migration occurs, this will be documented and you will receive full medical care at no additional cost to you."
- **C2 reversal confirmation:** The Nguyen family complaint states exactly: "The form he signed says nothing about the device moving in his body or that one in thirty people might need a second operation." The v2.3 Section 4.4 language is precisely what was missing from v2.1 and what the complaint invokes. The gap is not semantic -- it is the exact risk that materialized.
- **Settlement impact note:** "For reference: The Nguyen family complaint specifically invokes the risk of device migration and the approximately 3.2% rate. v2.1 does not disclose device migration as a named risk category. v2.3 Section 4.4 discloses it explicitly with the specific rate. The consent form used was v2.1."

**Length estimate:** ~1,400 words, ~2,100 tokens

---

### irb_preliminary_findings.md (Update 3, before R10)

**Content key points:**
- Title: `IRB Preliminary Findings -- CARDIOFIX-2 Protocol Consent Review (Protocol #PHM-2024-CR-047)`
- Date: W3 (approximately 3 weeks after complaint received)
- From: Dr. Amara Okonkwo, IRB Chair
- To: Dr. Victor Osei (PI), Dr. Kenji Tanaka (Department Head), Jennifer Wu (Legal Counsel), Dr. Hiroshi Sato (Co-PI, Stanford)
- **Key evidence (C4 reversal trigger):**
  - "Based on the complete evidentiary record reviewed to date -- including the research coordinator's contemporaneous field notes, the two consent form versions (v2.1 and v2.3), the participant enrollment log, and the PI's account -- the IRB has made the following preliminary determination:"
  - "**Finding 1:** The use of consent form version 2.1 for the enrollment of Participant 009 on [W0+3 date] constitutes a protocol deviation. Version 2.3 was the only authorized consent form as of [W0-6], six weeks prior to the enrollment. This finding is not disputed."
  - "**Finding 2:** The coordinator's contemporaneous field notes document a consent session of approximately 8 minutes, the exclusion of the participant's designated support person, and the absence of initials on risk sections 4.3 and 4.4. These observations are not consistent with the PI's account of a thorough consent session including verbal disclosure of all risks."
  - "**Finding 3:** There is no contemporaneous documentation of verbal disclosure of the device migration risk (Section 4.4 content) during the consent session. The PI's account of verbal disclosure is asserted post-hoc and is not corroborated by the coordinator's notes."
  - "**Preliminary conclusion:** The IRB characterizes this matter as a **potential regulatory violation** under 21 CFR 50.25 (elements of informed consent), specifically the requirement to disclose reasonably foreseeable risks. This differs from the preliminary characterization offered in early correspondence (documentation gap), which was based on incomplete review of the coordinator's record."
  - "**Required actions:** (1) Voluntary disclosure to FDA under 21 CFR 312.66 within 30 days is strongly recommended. Failure to voluntarily disclose creates substantially elevated risk of penalty if FDA learns of the violation through other means. (2) NIH notification may be required under grant terms (R01-HL-2024-047). The PI and Department Head should consult with legal counsel and the NIH Program Officer. (3) The IRB will conduct a formal investigation. Trial enrollment is suspended pending completion of the investigation."
- **C4 reversal:** The letter explicitly acknowledges the Phase 1 characterization ("documentation gap") and explains why the full evidentiary record changes it ("this differs from the preliminary characterization... which was based on incomplete review").

**Length estimate:** ~800 words, ~1,200 tokens

---

### osei_irb_response.md (Update 4, before R11)

**Content key points:**
- Title: `Response to IRB Preliminary Findings -- CARDIOFIX-2 Protocol (Protocol #PHM-2024-CR-047)`
- Date: W3+3 (3 days after preliminary findings issued)
- From: Dr. Victor Osei, PI
- To: Dr. Amara Okonkwo (IRB Chair), with copies to Dr. Tanaka, Jennifer Wu, Dr. Sato
- **Key evidence (genuine regulatory ambiguity, test of agent nuance):**
  - "I respectfully disagree with the IRB's preliminary finding that the consent process constituted a potential regulatory violation."
  - "**On verbal disclosure:** 21 CFR 50.25 requires that subjects be provided the elements of informed consent. The regulation does not require that the specific text of the consent form be read verbatim. A clinically equivalent verbal explanation of the risks satisfies the regulatory standard. I provided Mr. Nguyen with a verbal summary of the device risks, including the possibility of device migration. The absence of this in my coordinator's notes reflects a documentation gap, not an absence of the disclosure itself."
  - "**On session duration:** The regulation does not specify a minimum session duration. An experienced clinician can communicate essential information more efficiently than a protocol minimum duration might suggest. The 8-minute figure in the coordinator's notes reflects the formal session only -- the patient and I had a clinical conversation earlier in the day that addressed device risks as part of routine pre-procedure counseling."
  - "**On the deviation log entry:** The existence of a deviation log entry demonstrates that my team was aware of and actively managing the form version issue -- this is evidence of compliance culture, not non-compliance."
  - "**On the absent initials:** The absence of initials on sections 4.3 and 4.4 is a documentation deficiency, not evidence that the sections were not discussed. Mr. Nguyen may have inadvertently skipped those initialing lines."
- **What this response does NOT address:** (1) Why Rosa Nguyen was excluded. (2) Why the "clinical conversation earlier in the day" is not documented anywhere. (3) Why the deviation log entry was never formally filed. (4) Why the form version issue was not corrected before enrollment.
- **Regulatory ambiguity note (for agent assessment):** Osei's argument on verbal disclosure standard is partially valid -- courts have upheld verbal disclosure as supplementing (not replacing) the consent form in some jurisdictions. However, the argument is substantially weakened by the complete absence of documentation and the fact that no contemporaneous record corroborates the claimed verbal disclosure. Probability of this defense prevailing: approximately 25-35%.

**Length estimate:** ~700 words, ~1,050 tokens

---

## 6. Total Workspace Token Estimate

| Category | Files | Token Estimate |
|---|---|---|
| Fixed agent config (5 files) | AGENTS.md, IDENTITY.md, SOUL.md, USER.md, TOOLS.md | ~2,000 tokens |
| Initial scenario files (7 files) | trial_protocol_summary.md, consent_form_v2.1.md, irb_approval_letter.md, participant_enrollment_log.md, research_coordinator_log_partial.md, family_complaint_letter.md, trial_device_ifu.md | ~6,900 tokens |
| Update 1 files (1 file) | coordinator_field_notes.md | ~1,200 tokens |
| Update 2 files (1 file) | consent_form_v2.3_irb.md | ~2,100 tokens |
| Update 3 files (1 file) | irb_preliminary_findings.md | ~1,200 tokens |
| Update 4 files (1 file) | osei_irb_response.md | ~1,050 tokens |
| **Total workspace** | **16 files** | **~14,450 tokens** |

Remaining token budget for sessions: ~350K - 14.5K = ~335.5K tokens across 6 history sessions + 1 main session. Achievable given the session loop counts specified in layer2.
